Sandoz Expands Diabetes Drug Access in New Markets
New regulatory approvals in Brazil and Canada may affect treatment access for patients managing diabetes and obesity.
Updated on Oct. 28, 2026 in Diabetes
Live Poll
Do you trust pharmaceutical companies to handle supply constraints without compromising long-term financial stability?
Sandoz reported third-quarter net sales of $2.94 billion alongside updated financial guidance due to supply constraints in its biosimilars unit. The company also received new regulatory approvals in Brazil and Canada for its diabetes and obesity medications.
Why it matters
Changes in drug production and regulatory approvals can influence global access to essential treatments for conditions like diabetes. Patients relying on these medications should monitor for future updates regarding drug availability and manufacturing shifts.
Sandoz reported third-quarter net sales of $2.94 billion and a 17% growth in biosimilars unit sales compared to the prior year. While these results reflect current market performance, the impact of recent supply constraints on product availability is still being monitored.
The players
Sandoz
A global pharmaceutical company specializing in biosimilars and generic medications for chronic conditions.
The details
Sandoz utilizes large-scale production networks to manufacture biosimilars, which are complex biological medications that function similarly to reference products. The company is currently managing supply constraints that have necessitated a revision of their financial guidance. Meanwhile, the organization is expanding its regulatory footprint, having secured approvals for diabetes and obesity treatments in Brazil and Canada.
Timeline
March 2026: Sandoz filed an anti-dumping complaint regarding amoxicillin.
September 2026: The company hosted its annual capital markets day.
October 28, 2026: Sandoz released updated 2026 financial guidance.
2035: Target year for the company to double its annual net sales.
2040: Target year to reach a portfolio of 100 biosimilar drugs.
Health Landscape
The pharmaceutical industry is currently focused on scaling biosimilar production to lower treatment costs for chronic conditions. This report follows the company's long-term strategy to expand its portfolio to 100 drugs by 2040.
New regulatory approvals for diabetes and obesity drugs in Brazil and Canada represent potential changes in treatment availability for those regions. These developments are worth discussing with your physician to understand how they might influence your care options.
The takeaway
Sandoz is navigating supply constraints while simultaneously seeking to expand its global portfolio of diabetes and obesity treatments. Patients should consult their healthcare provider to stay informed about changes to the local availability of essential medications.
Further reading
Learn more about the latest developments in treatment options on our Diabetes page.
Live Poll
Do you trust pharmaceutical companies to handle supply constraints without compromising long-term financial stability?
